title: Concurrent Pneumocystis carinii and cytomegalovirus pneumonia after autologous peripheral blood stem cell transplantation.
abstract: A 46-year-old woman developed concurrent CMV and Pneumocystis carinii pneumonia (PCP) 140 days after autologous peripheral blood stem cell transplantation (APBSCT) for AML. She was seropositive for CMV before undergoing APBSCT and had required prednisone for immune thrombocytopenia and allergic dermatitis for 9 weeks prior to the onset of pneumonia. She had also been receiving PCP prophylaxis with pentamidine aerosol every month for 3 months before developing symptoms. The pneumonia was complicated by severe hypoxia, requiring ventilator support and pneumothorax requiring chest tube thoracostomy. She recovered following treatment with trimethoprim-sulfamethoxazole (TMP-SMX), prednisone, gancyclovir and intravenous immunoglobulin. Although the overall incidence of severe CMV disease is low after APBSCT, preventive measures such as surveillance culture and secondary prophylaxis with gancyclovir may be warranted in patients whose cellular immune response is further compromised by corticosteroid use or other factors.
authors.affiliation: Department of Medicine, Washington Hospital Center, DC 20010, USA.
authors.forename: W M
authors.initials: WM
authors.lastname: Chuu
authors.forename: J P
authors.initials: JP
authors.lastname: Catlett
authors.forename: D J
authors.initials: DJ
authors.lastname: Perry
authors.forename: L G
authors.initials: LG
authors.lastname: Geddes
authors.forename: P D
authors.initials: PD
authors.lastname: Levit
authors.forename: C S
authors.initials: CS
authors.lastname: Levy
authors.forename: M K
authors.initials: MK
authors.lastname: Buick
authors.forename: V
authors.initials: V
authors.lastname: Malkovska
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008875:Middle Aged; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D011024:Pneumonia, Viral / Q000150:complications / Q000188:drug therapy / Q000209:etiology*; D011241:Prednisone / Q000009:adverse effects; D014182:Transplantation, Autologous; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000998:Antiviral Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D015774:Ganciclovir; D011241:Prednisone